Posted on September 21, 2020 by Sitemaster
Roche/Genentech’s investigational drug ipatasertib has demonstrated a small but statistically significant benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who had tumors exhibiting loss of the phosphatase and tensin (PTEN) homolog: a 2-month improvement in median radiographic progression-free survival (rPFS). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, ipatasertib, IPATential150, loss, metastatic, PTEN | 7 Comments »
Posted on September 14, 2017 by Sitemaster
Overweight and obese prostate cancer patients are often advised to lose weight prior to surgery for the treatment of localized forms of prostate cancer. But is this really, always, a good idea? … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: loss, obesity, overweight, pre-surgery, prostatectomy, radical, weight | 2 Comments »
Posted on February 23, 2015 by Sitemaster
One of the most important things we patients want to know about any treatment is what kind of potency we can expect afterwards. Urinary and rectal dysfunctions are often measured and reported by investigators, but sexual dysfunction is rarely reported or measured. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: aging, brachytherapy, erectile, function, loss, Treatment | 4 Comments »
Posted on April 2, 2014 by Sitemaster
The degree to which drugs like sildenafil (Viagra) and taldalafil (Cialis) may help patient to maintain erectile function after treatment for localized prostate cancer has long been open to question. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: Cialis, erectile, function, loss, PDE-5, Prevention, radiation, sexual, tadalafil | 9 Comments »
Posted on September 20, 2012 by Sitemaster
Unsurprisingly, according to a new article in the Journal of Clinical Oncology, long-term androgen deprivation therapy (ADT) is closely associated with loss of lean muscle mass (known as sarcopenia) in men being treated for prostate cancer. However, this appears to be the first time anyone has shown there is an age-related factor that is relevant to the degree of loss of lean muscle. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: ADT, androgen deprivation, lean, loss, mass, muscle | 4 Comments »
Posted on October 15, 2010 by Sitemaster
Initiation of androgen deprivation therapy (ADT) has long been associated with the loss of lean muscle mass and a gain in mass of fatty tissue, leading toward an overall weight gain over time. However, data from the “real world” on the degree to which ADT actually affects body mass has been very limited. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, gain, loss, weight | 4 Comments »
Posted on May 25, 2010 by Sitemaster
A new study has shown that the generically available, oral, bisphosphonate risedronate (Actonel) can prevent bone loss and related effects in patients receiving hormonal therapy for prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bisphosphonate, bone, hormone, loss, risedronate, therapy, turnover | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 